SEC Form 4 · accession 0001193125-26-269694
Syndax Pharmaceuticals Inc · SNDX
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Nicholas A.J. Botwood
Officer — Head of R&D, CMO
Period of report
Jun 11, 2026
Accepted (ET)
Jun 12, 2026 · 5:09 pm EDT
Rule 10b5-1 plan
yes — trade under a plan
Issuer CIK
0001395937
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common Stock | Jun 11, 2026 | M | 22,515 | $13.82 | A | 95,165 | D | |
| Common StockF2 | Jun 11, 2026 | S | 34,280 | $18.00 | D | 60,885 | D | |
| Common Stock | Jun 12, 2026 | M | 31,235 | $13.82 | A | 92,120 | D | |
| Common StockF3 | Jun 12, 2026 | S | 31,235 | $18.14 | D | 60,885 | D |
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Stock options (Right to buy)F4 | $13.82 | Jun 11, 2026 | M | 22,515 | A | — | May 31, 2035 | Common Stock | 22,515 | 0 | D |
| Stock options (Right to buy)F4 | $13.82 | Jun 12, 2026 | M | 31,235 | A | — | May 31, 2035 | Common Stock | 31,235 | 0 | D |
Explanation of responses
- F1The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 plan adopted by the Reporting Person. Following the sales reported in this Form 4, the Reporting Person has a total of 16,537 options to purchase shares of common stock that are vested and immediately exercisable and a total of 289,413 options to purchase shares of common stock that have not yet vested.
- F2These transactions were executed in multiple trades at prices ranging from $17.31 to $18.10. The price reported above reflects the weighted-average sale price of all transactions executed on that date.
- F3These transactions were executed in multiple trades at prices ranging from $18.00 to $18.32. The price reported above reflects the weighted-average sale price of all transactions executed on that date.
- F4The shares sold in this transaction were fully vested.